NANTES

Axe : Cancers cutanés

Objectif(s) poursuivi(s)
Les activités de recherche du service de dermatologie du CHU de Nantes sont organisées selon 3 principaux axes :

  1. développement et réalisation d’essais cliniques dans les cancers cutanés,
  2. recherche translationnelle, axée majoritairement sur le microenvironnement tumoral ainsi que le transfert adoptif de lymphocytes dans le mélanome,
  3. épidémiologie et prévention du mélanome et des cancers cutanés non-mélanome.

Collaboration(s) avec le(s) laboratoire(s)
BMS, ROCHE, MSD, Amgen, Novartis, Incyte, Pierre-Fabre oncologie

Site internet
http://www.crcina.org/recherche/departement-1-incit/equipe-02-clinical-and-translational-research-in-skin-cancer/

Principales publications
Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668. PubMed PMID: 30073321; PubMed Central PMCID: PMC6233771.

Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13. PubMed PMID: 29908991.

Knol AC, Nguyen JM, Pandolfino MC, Denis MG, Khammari A, Dréno B. PD-L1 expression by tumor cell lines: A predictive marker in melanoma. Exp Dermatol. 2018 Jun;27(6):647-655. doi: 10.1111/exd.13526. PubMed PMID: 29505109.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma. Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488.Epub 2018 Feb 13. PubMed PMID: 29438370; PubMed Central PMCID: PMC5877437.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018. PubMed PMID: 29399408; PubMed Central PMCID: PMC5790392.

Simon S, Vignard V, Varey E, Parrot T, Knol AC, Khammari A, Gervois N, Lang F, Dreno B, Labarriere N. Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy. Cancer Res. 2017 Dec 15;77(24):7083-7093. doi: 10.1158/0008-5472.CAN-17-1856. Epub 2017 Dec 6. PubMed PMID: 29212853.

Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Khammari A, Dréno B, Denis MG. Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients. Ann Biol Clin (Paris). 2017 Dec 1;75(6):619-630. doi: 10.1684/abc.2017.1305. Review. PubMed PMID: 29192597.

Grob JJ, Mortier L, D’Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen 2017-000203. eCollection 2017. PubMed PMID: 29177094; PubMed Central PMCID: PMC5687540.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi: 10.1111/pcmr.12670. Epub 2017 Dec 10. PubMed PMID: 29156488.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2. PubMed PMID: 28928380; PubMed Central PMCID: PMC5605517.

de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0. PubMed PMID: 28646893; PubMed Central PMCID: PMC5483259.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician’s choice in CD30 positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555 566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. PubMed PMID: 28600132.

bWongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 1;23(17):5238-5245. doi: 10.1158/1078-0432.CCR-17 0172. Epub 2017 May 23. PubMed PMID: 28536307.

Axe : Pathologies inflammatoires

L’axe des pathologies inflammatoires est orienté essentiellement sur l’étude des mécanismes physiopathologiques impliqués dans l’acné et la maladie de Verneuil

Objectif(s) poursuivi(s)
Étudier l’impact du microbiote cutané, notamment C.acnes, dans le développement des réactions inflammatoires impliquées dans la physiopathologie de l’acné.
Concevoir de nouvelles approches thérapeutiques alternatives à l’antibiothérapie dans le traitement de l’acné.

Collaboration(s) avec le(s) laboratoire(s)
Galderma, La Roche Posay, NAOS, Vichy

Principales publications
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Kerrouche N, Tan J. Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison. Am J Clin Dermatol. 2018 Apr;19(2):275-286. doi: 10.1007/s40257-018-0352-y. PubMed PMID: 29549588; PubMed Central PMCID: PMC5978908.

Dagnelie MA, Khammari A, Dréno B, Corvec S. Cutibacterium acnes molecular typing: time to standardize the method. Clin Microbiol Infect. 2018Nov;24(11):1149-1155. doi: 10.1016/j.cmi.2018.03.010. Epub 2018 Mar 12. Review. PubMed PMID: 29544912.

Dréno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018 May;32(5):812-819. doi: 10.1111/jdv.14820. Epub 2018 Feb 15. Review. PubMed PMID: 29377341; PubMed Central PMCID: PMC5947266.

Frenard C, Dagnelie MA, Khammari A, Saint-Jean M, Boisrobert A, Corvec S, Dreno B. Do Cutibacterium acnes and Staphylococcus aureus define two different types of folliculitis?: Bacteriological study of scalp folliculitis. J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e266-e268. doi: 10.1111/jdv.14793. Epub 2018 Jan 31. PubMed PMID: 29341254.

Poli F, Auffret N, Claudel JP, Leccia MT, Dreno B. AFAST: an adult female acne treatment algorithm for daily clinical practice. Eur J Dermatol. 2018 Feb 1;28(1):101-103. doi: 10.1684/ejd.2017.3157. PubMed PMID: 29171399.

Dagnelie MA, Corvec S, Saint-Jean M, Bourdès V, Nguyen JM, Khammari A, Dréno B. Decrease in Diversity of Propionibacterium acnes Phylotypes in Patients with Severe Acne on the Back. Acta Derm Venereol. 2018 Feb 7;98(2):262-267. doi: 10.2340/00015555-2847. PubMed PMID: 29136261.

Tan J, Bourdès V, Bissonnette R, Petit B Eng L, Reynier P, Khammari A, Dreno B. Prospective Study of Pathogenesis of Atrophic Acne Scars and Role of Macular Erythema. J Drugs Dermatol. 2017 Jun 1;16(6):566-572. PubMed PMID: 28686774.

Axe : Télémédecine

L’axe des pathologies inflammatoires est orienté essentiellement sur l’étude des mécanismes physiopathologiques impliqués dans l’acné et la maladie de Verneuil

Objectif(s) poursuivi(s)
Développement d’un suivi en téléconsultation pour les patients résidents en EHPAD et porteurs de plaies chroniques.
Consultations effectuées par le Dr FRENARD .

Collaboration(s) avec le(s) laboratoire(s)
CHU de Caen via le réseau TELAP